
The 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain, from October 23 to 27, local time. As one of the most influential comprehensive academic events in global oncology, the ESMO Congress brings together leading international experts, clinical researchers, and pharmaceutical innovators to showcase cutting-edge advances in cancer diagnosis and treatment.
KRAS is one of the key driver genes in pancreatic cancer. Approximately 90% of patients with pancreatic ductal adenocarcinoma (PDAC) harbor KRAS mutations, with KRAS G12D accounting for approximately 40% of cases. However, this target was long considered “undruggable.” In recent years, major breakthroughs have fundamentally changed this landscape.
At this year’s ESMO Congress, Professor Chenlei Wen, from the team led by Professor Baiyong Shen at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, presented the preliminary results of a Phase II study in a rapid oral presentation. The study evaluated the KRAS G12D inhibitor HRS-4642 in combination with chemotherapy, with or without adebrelimab, as perioperative treatment for patients with KRAS G12D-mutated pancreatic cancer (Abstract No. LBA85).
At the congress, Oncology Frontier – Digestive Diseases invited Professor Chenlei Wen to discuss the rationale for moving KRAS-targeted agents from later-line treatment into the perioperative setting, mechanisms of resistance to KRAS-targeted therapy, and potential strategies to overcome these challenges. The following is an edited summary of the interview.
Q1
Several studies of KRAS-targeted therapies were presented at this year’s congress. From daraxonrasib in later-line treatment to HRS-4642 in the perioperative setting, how do you view the overall strategy of moving KRAS-targeted agents into earlier lines of treatment and the perioperative setting?
Professor Chenlei Wen: KRAS inhibitors can be considered landmark drugs in the treatment of pancreatic cancer. Daraxonrasib, for example, has already received regulatory approval in the United States. However, we must also recognize that this success has so far been demonstrated primarily in later-line treatment of advanced disease and is not yet sufficient to achieve a cure for pancreatic cancer.
Therefore, the key to advancing toward curative treatment is to move therapeutic intervention earlier. Pancreatic cancer is often referred to as the “king of cancers” primarily because of its high propensity for recurrence and metastasis. Surgery remains the only treatment that offers the possibility of a cure, yet many patients have already lost the opportunity for upfront surgery by the time they are diagnosed.
In light of this reality, the other treatment strategies pursued at our center are all directed toward the same goal: doing everything possible to improve the likelihood of successful surgery and increase the number of patients who have the opportunity to undergo curative resection.
Guided by this philosophy, our team conducted a Phase II study evaluating the KRAS G12D inhibitor HRS-4642 in combination with chemotherapy, with or without adebrelimab, as perioperative treatment for patients with KRAS G12D-mutated pancreatic cancer. This study combines three therapeutic approaches—chemotherapy, targeted therapy, and immunotherapy. On the one hand, this strategy aims to create a more favorable therapeutic window for surgery. On the other, it seeks to inhibit tumor growth through the complementary effects of these three modalities and help patients’ own immune systems establish a sustained state of equilibrium with the tumor. Ultimately, this may further reduce the risk of postoperative recurrence and bring us closer to the goal of achieving a cure.
Overall, we believe the strategic development of KRAS-targeted agents should progress from later-line treatment toward earlier lines and the perioperative setting. The direction is clear. For patients who have already developed metastatic disease, we should not abandon active treatment. For patients with early-stage disease, we should move multidimensional combination strategies involving chemotherapy, targeted therapy, and immunotherapy further forward in the treatment pathway, giving more patients the opportunity to achieve a cure.
Q2
Although KRAS-targeted therapy has achieved important breakthroughs, drug resistance remains an inevitable challenge. What do you consider the main mechanisms of resistance to KRAS inhibitors at present? Where do you see opportunities to overcome resistance in the future, particularly through combination strategies?
Professor Chenlei Wen: Resistance is indeed an unavoidable challenge in KRAS-targeted therapy. From a mechanistic perspective, Revolution Medicines, a pioneer in the field of RAS inhibitors, recently published a paper on mechanisms of resistance to KRAS-targeted therapy. One of its key findings was that RAS inhibitors can induce increases in RAS gene copy number and expression.
Based on this resistance mechanism, one intuitive approach would be to continuously increase drug doses to counteract resistance. In practice, however, the major limitation of RAS inhibitors such as daraxonrasib is their relatively high toxicity, which restricts the extent to which doses can be increased. In other words, attempting to overcome resistance simply by escalating the dose is a difficult and largely passive strategy.
Just as a battle cannot be won through frontal assaults alone and may require breakthroughs from the flanks, our approach to overcoming resistance should also involve looking beyond the RAS target itself. This means developing additional therapeutic targets outside the RAS pathway while actively advancing combination strategies.
To address resistance to RAS-targeted agents, we are currently exploring combinations of drugs directed against specific RAS mutation sites with pan-RAS inhibitors. At the same time, we are continuously moving these treatments into earlier lines of therapy to create better treatment opportunities for patients and potentially even enable them to undergo surgery.
Whether treating patients with advanced disease or those receiving neoadjuvant therapy, earlier use of these targeted agents may often translate into greater survival benefits.
Study Overview
Background
Although KRAS G12D-targeted therapies have made progress in advanced PDAC, perioperative treatment continues to rely on chemotherapy regimens such as gemcitabine plus nab-paclitaxel (GnP). This report presents data on the use of the KRAS G12D inhibitor HRS-4642 in combination with GnP, with or without adebrelimab, as perioperative treatment for patients with resectable or borderline resectable KRAS G12D-mutated pancreatic cancer.
Methods
This was an open-label, prospective Phase II study enrolling treatment-naive patients with resectable, KRAS G12D-mutated pancreatic cancer.
Patients received eight cycles of perioperative treatment administered every three weeks. The regimen consisted of:
- HRS-4642: 500 mg on Day 1 and 1,200 mg on Day 8;
- GnP: nab-paclitaxel 125 mg/m² on Days 1 and 8, plus gemcitabine 1,000 mg/m² on Days 1 and 8;
- Adebrelimab: 1,200 mg on Day 1, administered either without adebrelimab (Cohort 1) or with adebrelimab (Cohort 2).
Approximately four cycles were administered preoperatively and four cycles postoperatively.
The primary endpoints were objective response rate (ORR), assessed according to RECIST v1.1, and safety. Secondary endpoints included the R0 resection rate, major pathological response (MPR) rate, event-free survival (EFS), overall survival (OS), and exploratory biomarkers.
Results
As of September 3, 2026, 30 patients had been enrolled in each cohort.
Regarding baseline characteristics, the median age was 64 years in both Cohort 1 and Cohort 2. All patients in both cohorts had an ECOG performance status of 1. The proportion of male patients was 70% versus 60%, respectively. The distribution of patients with Stage I/II/III disease was 3%/67%/30% in Cohort 1 and 0%/60%/40% in Cohort 2.
All patients received neoadjuvant treatment and completed at least one post-treatment assessment.
Safety: The incidence of Grade ≥3 treatment-related adverse events (TRAEs) was 47% in Cohort 1 and 53% in Cohort 2. The most common events were neutropenia and leukopenia. No fatal TRAEs occurred, and no patients were unable to undergo surgery because of TRAEs.
Efficacy: Tumor shrinkage was observed in all patients. The ORR was 63% in Cohort 1 and 87% in Cohort 2, with median times to response of 51 and 49 days, respectively. The 6-month EFS rates were 87% and 96%, respectively, while OS data remained immature.
A total of 23 patients in Cohort 1 and 29 patients in Cohort 2 underwent surgery. Among patients who underwent resection, the R0 resection rate was 100% in both cohorts, and the MPR rate was 17% in each cohort.
All patients whose baseline CA19-9 levels were above the upper limit of normal (ULN) experienced a reduction of at least 50%.
Conclusions
HRS-4642 in combination with GnP demonstrated promising neoadjuvant activity in patients with KRAS G12D-mutated pancreatic cancer, with a high ORR, a high R0 resection rate, encouraging MPR, and manageable safety. The addition of adebrelimab showed potential to further enhance treatment efficacy.